|
Dr. Nolan's experience in both academia and
the biotech industry will help fuel GeneEd's continuing acceptance
as the leader in enterprise-wide e-Learning solutions for the life
sciences
San Francisco, Calif.
January 16, 2001— GeneEd (www.GeneEd.com),
the leading provider of e-Learning solutions for the life sciences,
has today announced the appointment of Dr. Garry Nolan to its Scientific/Educational
Advisory Board.
Dr. Nolan is an Associate Professor in the Department
of Molecular Pharmacology at Stanford University's School of Medicine.
Dr. Nolan is also a co-founder of Rigel, Inc., a functional genomics
company, headquartered in San Francisco.
"Dr. Nolan brings a new and exciting dimension
to our board," said Sunil Maulik, Ph.D., CEO and Co-Founder of GeneEd.
"Because of his success at Stanford and Rigel, Dr. Nolan understands
the educational and training needs unique to both academia and industry.
His experience will allow us to be sensitive to the specific needs
in both of these arenas. That way, we can provide enterprise-wide
e-Learning solutions that help life science professionals at universities
and biotech companies alike stay competitive in this post genomics
era."
"One of the most difficult aspects of the educational
process is capturing expertise in a manner that is accessible to
many," said Dr. Nolan. "The second most difficult part is conveying
that information effectively. I am thrilled to be a part of an enterprise
whose technological focus will be to formalize both realms coherently.
GeneEd, I believe, will be at the lead for this in the areas of
biotechnology and pharmaceutical design. I only expect this to translate
into other potent forms of learning approaches."
Dr. Nolan's current research at Stanford focuses
on gene transfer technologies, intracellular combinatorial libraries,
and gene regulation. His work covers the areas of autoimmunity (diabetes
and arthritis), HIV and cancer. During his Ph.D work with Dr. Len
Herzenberg, he developed technologies now used in laboratories worldwide
that allowed gene expression analysis at the single cell level.
During postdoctoral work with Nobel Laureate David Baltimore, he
isolated critical genes that lay at a focal point for immune regulation
and developed gene delivery technologies that are a basis for gene
therapy procedures used internationally. The intracellular combinatorial
approaches pioneered in Dr. Nolan's laboratory are also being used
in Rigel's drug discovery activities.
Dr. Nolan has authored over sixty research publications
and holds nine patents or patents pending. In 1999, Dr. Nolan co-authored,
"Gene Therapy and Protein Expression Technologies", and has contributed
chapters to eight other books. Dr. Nolan has given numerous invited
lectures worldwide. He is a member of the American Association for
the Advancement of Science, Society of Developmental Biology, American
Society for Microbiology and the American Society for Gene Therapy.
He has served on a number of editorial boards including, Chemistry
and Biology, Gene Therapy & Molecular Biology, Cells to Genes and
Molecular Therapy (American Cancer Society).
Dr. Nolan received his B.S. from Cornell University
and his Ph.D. from Stanford University.
About GeneEd, Inc.
GeneEd, Inc. was founded in 1997 to provide life science and health
e-Learning solutions through the creation of compelling, multimedia-based
training, delivered via e-media such as the Internet. GeneEd offers
an expanding selection of courses and custom services in the areas
of genomics, research, discovery, development, manufacturing, technical
sales training, strategic marketing and consumer education.
Last year, GeneEd announced an agreement to join
with Scientific American to develop a series of educational courseware
products bearing the Scientific American and Powered by GeneEd™
brand names. The first of the Scientific American 2000 series courses,
titled Bioinformatics 2000: An Overview, was introduced in October
2000.
GeneEd has also announced strategic distribution
relationships with Cambridge Healthtech Institute (CHI), Sumitomo
Corporation, Incyte Genomics and MedSchool.com. GeneEd currently
offers a suite of five introductory courses entitled "Biopharmaceutical
Technology 101" (available at www.GeneEd.com). In addition, advanced
courseware in SNPs, Biochips/Microarrays and Bioinformatics were
recently introduced. Additional courseware in Molecular Diagnostics
(advanced) and Molecular Biology (introductory) will be released
shortly. These courses are focused on the emerging technologies
in the post-genomic era of discovery, development and personalized
medicine.
GeneEd's custom products have already been successfully
used by "smart" companies such as Celera, Incyte, ALZA, Bio-Rad,
Vical and Compugen.
Recent news releases and other information are
available on GeneEd's Internet home page at www.GeneEd.com.
GeneEd, Inc. is a privately held company headquartered
at 209 9th Street, San Francisco, California, 94103. Phone: 415-861-7627.
Fax: 415-861-5170. Web site: www.GeneEd.com.
back to top
|
